Ketotifen Teva

Ketotifen, the active ingredient in Ketotifen Teva, is an antihistamine presented as an oral formulation for oral use. It is used to manage allergic conditions and to help prevent asthma symptoms in patients with a history of allergic disease.

GNH USA supplies Ketotifen Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketotifen is an antihistamine that acts on allergic and asthmatic pathways, providing symptom relief and prophylaxis.

Allergic rhinitis: reduces nasal congestion, itching and sneezing associated with seasonal or perennial allergies. Allergic conjunctivitis: alleviates eye itching, redness and tearing caused by allergen exposure. Asthma prophylaxis: helps prevent bronchial hyper‑responsiveness and asthma attacks when used as part of a long‑term management plan.

Ketotifen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness or fatigue - Dry mouth or throat - Headache - Nausea or abdominal discomfort - Weight gain - Blurred vision or eye irritation

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe skin rash or hypersensitivity reactions - Hepatic dysfunction or elevated liver enzymes - Anaphylaxis or severe allergic response - Blood dyscrasias such as agranulocytosis - Severe neutropenia or thrombocytopenia

When using Ketotifen, certain precautions should be observed to ensure safety and effectiveness.

Assess hepatic function: evaluate liver status before initiating therapy. Monitor for sedation: advise patients not to operate machinery if drowsy. Avoid driving or hazardous tasks: especially during dose titration. Use caution in glaucoma: may increase intra‑ocular pressure. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

Ketotifen can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other sedating antihistamines: additive CNS depression. - Central nervous system depressants (e.g., benzodiazepines, opioids): enhanced drowsiness. - Alcohol: may intensify sedation and impair coordination.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase ketotifen plasma levels. - Anticholinergic agents: could exacerbate dry mouth. - Beta‑blockers: may blunt bronchodilator response in asthmatic patients.